Home » FDA Plans Biosimilars Development Meeting Guidance in 2014
FDA Plans Biosimilars Development Meeting Guidance in 2014
The FDA plans to issue draft guidance by mid-2014 on the various product development meetings included in its proposed biosimilars user fee program. The program includes four such meetings, which allow for open sponsor-FDA communication during the development process, after an IND is filed and before a biosimilar 351(k) is filed. They also encourage multiple development approaches — a necessity for a biosimilars approval pathway, Momenta Pharmaceuticals Senior Vice President Bruce Leicher said Dec. 16 during the final public meeting on the proposed user fees.
Drug Industry Daily
Drug Industry Daily
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May